{"prompt": "['2017N330177_04', 'CONFIDENTIAL', '205678', '3.', 'INTRODUCTION', 'Multiple myeloma (MM) is an incurable malignancy and accounts for 1% of all cancers', 'and for 10% of all hematologic malignancies. Worldwide, approximately 103,000 new', 'cases are diagnosed annually, and an estimated 30,330 new cases and 12,650 deaths will', 'occur in the US in 2016 [Siegel, 2016]. There have been significant advances in', 'treatment for MM, including novel therapies like second and third -generation', 'proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and recent addition of', 'monoclonal antibodies (mAbs). Those advances have contributed to incremental gains in', 'PFS and OS, but most MM patients still relapse and ultimately develop resistance to', 'existing therapies. Therefore, there is an urgent need to develop treatments with novel', 'MOA which could potentially prevent the cross resistance to existing therapies [Kumar,', '2004]. Details of the characteristics of GSK2857916, nonclinical, and clinical activity', \"are provided in the Investigator's Brochure (IB) [GSK2857916 GlaxoSmithKline\", 'Document Number 2013N175128_04]', '3.1.', 'Study Rationale', 'Before the introduction of daratumumab, patients with disease that is refractory to both', 'immunomodulatory drugs and proteasome inhibitors (PIs) had a median overall survival', '(OS) ranging from 9 months [Kumar, 2012] to 12 months [Kumar, 2004; Kumar, 2003].', 'Daratumumab [DARZALEX, 2017], is a human IgGk monoclonal antibody that was', 'granted accelerated approval as monotherapy for the treatment of RRMM in the US in', 'November 2015 [Afifi, 2016] on the basis of the results from a Phase II monotherapy', 'study (n=106) which reported 29.2% ORR and mPFS 3.7 months in patients with', 'relapsed or refractory multiple myeloma. The median number of prior lines of treatment', 'reported in this study was 5.', 'Later, daratumumab has been approved in combination with', 'lenalidomide/dexamethasone, bortezomib/dexamethasone for patients who were', 'previously treated with at least one prior line, and in combination with pomalidomide and', 'dexamethasone for patients previously treated with at least 2 prior lines [DARZALEX,', '2017; Janssen-Cilag International NV, 2016].', 'While the data with daratumumab indicate that further prolongation of PFS can been', 'achieved, it is also increasingly recognized that patients continue to relapse after', 'treatment with daratumumab, and will need additional treatment options to control the', 'disease. Patients with MM who relapse after daratumumab therapy, have few treatment', 'options available and could benefit from treatment with a novel drug such as', 'GSK2857916.', 'GSK2857916 is a first in class, ADCC enhanced, humanized immunoglobulin G1 (IgG1)', 'antibody-drug conjugate (ADC) that binds specifically to B-cell maturation antigen', '(BCMA), a target present on mature B cells and on tumor cells in patients with MM [Tai,', '2015; Tai, 2006]. The antibody is conjugated to the microtubule inhibitor monomethyl', 'auristatin-F (MMAF), and is produced as an afucosylated form that generates an', 'enhanced antibody-dependent cellular cytotoxicity (ADCC) response. As demonstrated', '33']['2017N330177_04', 'CONFIDENTIAL', '205678', 'in the FTIH study this novel mechanism of action can be reasonably expected to', 'overcome cross resistance to existing therapies.', 'GSK2857916 has shown strong single-agent activity in the currently ongoing FTIH', 'study BMA117159.', 'Among the 35 participants receiving GSK2857916 at the RP2D of 3.4 mg/kg IV,', 'Q3W, the following results were observed:', 'Overall response rate (ORR) of 60% (95% CI: 42.1%, 76.1%)', 'Median progression-free survival (PFS) was 7.9 months (95% CI:3.1, -', 'months).', 'The ORR in 14 participants who failed prior daratumumab treatment was', '43% (95% CI: 17.7%, 71.1%), and the PFS in this subgroup was 6.8 mo.', 'Overall, GSK2857916 was well tolerated and adverse events were', 'manageable.', 'This data supports further development of GSK2857916 as monotherapy in patients', 'who failed an anti-CD38 antibody and are refractory to PI and IMiD.', '3.2.', 'Background - BCMA and Multiple Myeloma', 'B-cell maturation antigen (BCMA also referred to as TNFRSF17 or CD269) is a member', 'of the tumor necrosis factor (TNF) receptor superfamily and regulates a variety of', 'cellular functions. BCMA is expressed in mature B lymphocytes and binds to two TNF', 'family ligands BAFF (B-cell-activating factor belonging to the TNF family) and APRIL', '(a proliferation-inducing ligand) which promotes B-cell survival and proliferation. Mice', 'deficient for BCMA are viable, have normal B-cell development, and exhibit normal', 'humoral responses [Belnoue, 2008; Varfolomeev, 2004; Jiang, 2011]. BCMA is', 'expressed on malignant plasma cells in all MM patients [Tai, 2015; Tai, 2006]. The', 'restricted expression profile of BCMA in normal tissue, combined with its up-regulation', 'and recognized survival function in MM [Tai, 2006; Sanchez, 2012; Novak, 2004] makes', 'BCMA an attractive target for a therapeutic antibody with direct cell killing activity and', 'with minimal off target effects [Tai, 2015]. BCMA has been validated as a therapeutic', 'target in MM [Tai, 2015]. The BMA117159 study was the first time in human (FTIH)', 'study demonstrating single-agent activity of GSK2857916 in heavily pre-treated MM', 'participants. Chimeric Antigen Receptor T-Cells (CAR-T) based therapies targeting', 'BCMA have also demonstrated powerful activity against MM, with substantial albeit', 'reversible risks [Cohen, 2016]. Other approaches utilizing bispecific antibodies (BiTe)', 'have also entered development, but clinical results have not been reported at the time of', 'writing this protocol.', '3.3.', 'Antibody-Drug Conjugate GSK2857916', 'GSK2857916 is a first in class, ADCC-enhanced, humanized immunoglobulin G1 (IgG1)', 'antibody drug conjugate (ADC) that binds specifically to B-cell maturation antigen', '(BCMA), a target restricted to B cells at later stages of differentiation and expressed on', 'tumor cells of all patients with MM [Tai, 2015; Tai, 2006]. The antibody moiety of', 'GSK2857916 is produced as an afucosylated form that generates an enhanced antibody-', '34']\n\n###\n\n", "completion": "END"}